Trial
NCT02811679
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Amgen
Condition
Non-Hodgkin Lymphoma
Intervention
Blinatumomab
Why stopped
Study closed early due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-23